Nido Biosciences
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Nido Biosciences was a Watertown, Massachusetts neurobiotech founded in 2020 through 5AM Ventures' 4:59 Initiative, developing precision small-molecule medicines for severe neurological diseases. Its lead asset, NIDO-361, bound a unique site on the androgen receptor to correct transcriptional dysregulation in spinal and bulbar muscular atrophy (SBMA, Kennedy's disease). The company emerged from stealth in 2023 with $109 million in financing backed by 5AM Ventures, Abingworth, Bessemer Venture Partners, and Eli Lilly.
02 / Nido Biosciences FAILURE REASONS
Failure reasons
Nido's shutdown traces to a single binary event: in December 2025, CEO Jeremy Springhorn announced that the global Phase 2 trial of NIDO-361 in SBMA had missed its endpoints with no meaningful benefit. The company was a single-asset bet with no fallback—its platform had produced no second candidate, so the trial failure removed its reason to exist. With about $109 million raised and spent over five years and no strategic buyer willing to continue, the board chose to wind down in early 2026.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Nido Biosciences is founded through 5AM Ventures' 4:59 Initiative to develop precision small-molecule medicines for neurological diseases.
- Peak funding round
The company emerges from stealth with $109 million in seed, Series A and Series B financing, backed by 5AM Ventures, Abingworth, Bessemer, and Eli Lilly.
- Closure announced
In December 2025 the CEO announces the global Phase 2 trial of NIDO-361 in SBMA missed its endpoints; the company begins winding down, with full shutdown expected in early 2026.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Precision small molecules for neurological diseases
- 02
$109M raised; stealth exit in 2023; NIDO-361 for Kennedy's disease
- 03
Global Phase 2 missed endpoints in Dec 2025
- 04
No fallback pipeline; wind-down, shutdown in early 2026